Article thumbnail

HTPB effectively inhibits A549 xenograft growth without significant side effects.

By Jiunn-Min Shieh (187539), Tzu-Tang Wei (187542), Yen-An Tang (187547), Sin-Ming Huang (187551), Wei-Ling Wen (187554), Mei-Yu Chen (187558), Hung-Chi Cheng (187562), Santosh B. Salunke (187566), Ching-Shih Chen (11162), Pinpin Lin (187569), Chien-Tien Chen (187570) and Yi-Ching Wang (187572)


<p>(<b>A</b>) Balb/c nude mice bearing the established A549 tumors (∼50 mm<sup>3</sup>) were treated with HTPB via intraperitoneal (left panel) or oral administration (right panel) for three weeks (3 days/week). A known HDAC inhibitor, SAHA, was used for comparison in intraperitoneal experiments. The tumor volumes of mice were measured twice weekly. Points, mean; bars, ±SEM. Three mice per group for intraperitoneal injection and five mice per group for oral treatment were used in the xenograft experiment. (<b>B</b>) The tumor weights of mice were measured. P values were for comparisons with DMSO or vehicle control (* <i>P</i><0.05, ** <i>P</i><0.01). (<b>C</b>) HTPB treatments did not cause significant body weight loss of tested animals. (<b>D</b>) Hematological biochemistry tests including GOT, GPT, albumin and creatinine were examined and the results showed no significant differences between HTPB treatment and DMSO or solvent control.</p

Topics: Biochemistry, Molecular Biology, Biotechnology, Chemistry, Cancer, inhibits, a549, xenograft
Year: 2012
DOI identifier: 10.1371/journal.pone.0030240.g004
OAI identifier:
Provided by: FigShare
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.